NZ595812A - Replikin-sequences for preventing/treating influenza and determining infectivity/lethality - Google Patents

Replikin-sequences for preventing/treating influenza and determining infectivity/lethality

Info

Publication number
NZ595812A
NZ595812A NZ595812A NZ59581209A NZ595812A NZ 595812 A NZ595812 A NZ 595812A NZ 595812 A NZ595812 A NZ 595812A NZ 59581209 A NZ59581209 A NZ 59581209A NZ 595812 A NZ595812 A NZ 595812A
Authority
NZ
New Zealand
Prior art keywords
replikin
lethality
sequences
preventing
treating influenza
Prior art date
Application number
NZ595812A
Inventor
Samuel Bogoch
Elenore S Bogoch
Samuel Winston Bogoch
Anne Elenore Borsanyi
Original Assignee
Samuel Bogoch
Elenore S Bogoch
Samuel Winston Bogoch
Anne Elenore Borsanyi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/041565 external-priority patent/WO2009132209A2/en
Priority claimed from US12/429,044 external-priority patent/US20090269367A1/en
Priority claimed from US12/538,027 external-priority patent/US20100144589A1/en
Application filed by Samuel Bogoch, Elenore S Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi filed Critical Samuel Bogoch
Publication of NZ595812A publication Critical patent/NZ595812A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)

Abstract

595812 discloses vaccine comprising at least one protein fragment or peptide isolated from a hemagglutinin protein area of an isolate of influenza and at least one protein fragment or peptide isolated from a pB1 gene area of an isolate of influenza and a method of making said vaccine.
NZ595812A 2009-04-23 2009-10-16 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality NZ595812A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17211509P 2009-04-23 2009-04-23
PCT/US2009/041565 WO2009132209A2 (en) 2008-04-23 2009-04-23 Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US12/429,044 US20090269367A1 (en) 2008-04-23 2009-04-23 Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US17968609P 2009-05-19 2009-05-19
US18516009P 2009-06-08 2009-06-08
US12/538,027 US20100144589A1 (en) 2008-08-08 2009-08-07 Methods of predicting cancer lethality using replikin counts
US24600609P 2009-09-25 2009-09-25
PCT/US2009/061108 WO2010123519A1 (en) 2009-04-23 2009-10-16 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality

Publications (1)

Publication Number Publication Date
NZ595812A true NZ595812A (en) 2013-09-27

Family

ID=41528810

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595812A NZ595812A (en) 2009-04-23 2009-10-16 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality

Country Status (7)

Country Link
EP (1) EP2421546A1 (en)
AU (1) AU2009344843A1 (en)
CA (1) CA2759325A1 (en)
IL (1) IL215770A0 (en)
NZ (1) NZ595812A (en)
SG (2) SG175275A1 (en)
WO (1) WO2010123519A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012283914A1 (en) 2011-07-20 2014-01-30 Bogoch, Elanore S. Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
SG11201405447QA (en) 2012-03-09 2014-10-30 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus
WO2014165274A2 (en) * 2013-03-13 2014-10-09 Samuel Bogoch Methods of diagnosing, preventing, and treating drug-resistant pathogenic infections using replikin sequences
CN110680912B (en) * 2019-09-26 2021-08-17 中国农业大学 H3N2 and H3N8 subtype canine influenza bivalent inactivated vaccine as well as preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
EP1859063A4 (en) * 2005-02-16 2012-02-01 Bogoch Samuel Replikin peptides and uses thereof
CA2619174C (en) * 2005-08-15 2016-12-20 Vaxin, Inc. Immunization of avians by administration of non-replicating vectored vaccines
EP2010210A4 (en) * 2006-04-21 2010-07-21 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
CA2654178A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
KR20090050056A (en) * 2006-08-14 2009-05-19 메사츄세츠 인스티튜트 어브 테크놀로지 Hemagglutinin polypeptides, and reagents and methods
US20080241188A1 (en) * 2007-03-30 2008-10-02 Zeon Corporation Turkey herpesvirus vectored recombinant containing avian influenza genes

Also Published As

Publication number Publication date
AU2009344843A1 (en) 2011-11-10
CA2759325A1 (en) 2010-10-28
SG10201401532PA (en) 2014-08-28
WO2010123519A1 (en) 2010-10-28
SG175275A1 (en) 2011-11-28
IL215770A0 (en) 2012-01-31
EP2421546A1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
EP2078083A4 (en) A novel canine influenza virus and vaccine therefore
CL2020001852A1 (en) Processes for the preparation of s-ketamine or s-ketamine hydrochloride or products derived from it. (divisional request 201901066)
CY1116583T1 (en) CHEMICAL Poultry Flu VLPS
BRPI0713671A2 (en) DNA SEQUENCES, VECTORS AND PROTEINS OF HEMAGLUTININ FROM AVIAN INFLUENZA
WO2008121329A3 (en) Turkey herpesvirus vectored recombinant containing avian influenza genes
BR112012001171A2 (en) selection method. evolution and expression of an antibody fragment or antibody, methods of evolution and expression of an antibody and a protein, method of evolution and manufacture of a protein, method of evolution for enhanced expression and manufacture of a protein, method for identifying and produce a protein, and method of evolution of a protein.
NZ595812A (en) Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BRPI0906710B8 (en) Hepatitis b virus (hbv) hydrophobic modified pres derived peptide, peptide and pharmaceutical composition
BR112012029897A2 (en) method for reducing the amount of a serine protease or serine protease zymogen in a composition, method for preparing a composition, plasma derived protein composition, and method for treating a disease
RS20080138A (en) Vaccines and methods to treat canine influenza
MX2009006148A (en) Pathogen inducible plant trehalose-6-phophate phophatase gene promoters and regulatory elements.
WO2012112489A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EP3210622A3 (en) Recombinant avian paramyxovirus vaccine and method for making and using thereof
ATE462795T1 (en) AUTOACTIVATED RESISTANCE PROTEIN
AR087885A1 (en) USEFUL ENZYMES FOR THE FOOD INDUSTRY
CU24580B1 (en) ATTENUATED VECTORS OF INFLUENZA FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
EP3572507A4 (en) Expression method for haemocoagulase acutus recombinant protein
CO2017011778A2 (en) An inhibitor of csf-1r activity and pharmaceutical compositions comprising it
PL408649A1 (en) Influenza viruses haemagglutinin protein as the vaccine antigen
GT201300189A (en) PEST CONTROL METHODS IN SOYA
IL280628A (en) Methods for de novo protein sequencing
BR112016013157A2 (en) protease resistant peptides
ECSP099816A (en) A ROSE THAT CONTAINS FLAVONA AND METHOD FOR ITS PRODUCTION
BR112018072968A2 (en) protease resistant monolipidated peptides

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 OCT 2016 BY CPA GLOBAL

Effective date: 20140113

LAPS Patent lapsed